ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1823

Genome-Wide DNA Methylation Analysis in Familial Mediterranean Fever

Kader Cetin Gedik1, Desire Casares Marfil2, Busra Baser Taskin3, Elif Kilic Konte4, Sezgin Sahin4, Mckenna Bowes2, Ferhat Guzel5, Micol Romano6, Ozgur Kasapcopur7, Nuray Aktay Ayaz3, Erkan Demirkaya6 and Amr Sawalha2, 1UPMC Children's Hospital of Pittsburgh/University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3Istanbul University Medical School, Istanbul, Turkey, 4Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, 5Department of Research and Development, Ant Biotechnology, Istanbul, Turkey, 6University of Western Ontario, London, ON, Canada, 7Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey

Meeting: ACR Convergence 2025

Keywords: Autoinflammatory diseases, Epigenetics, Inflammation, innate immunity, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1809–1829) Pediatric Rheumatology – Basic Science Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Familial Mediterranean fever (FMF) is an autoinflammatory disease most commonly associated with biallelic mutations in the MEFV gene. Patients carrying the same pathogenic variant in MEFV can exhibit a broad spectrum of clinical phenotypes. Identifying factors contributing to this clinical variability is essential for understanding disease mechanisms. DNA methylation has been proposed as a potential modifier of MEFV mutations and clinical presentation. However, prior studies exploring this hypothesis included heterogeneous cohorts, lacked genome-wide methylation analyses, and yielded inconsistent findings. We aimed to investigate the role of DNA methylation in FMF using a genome-wide DNA methylation approach.

Methods: We conducted a cross-sectional, genome-wide DNA methylation analysis using whole blood samples from pediatric FMF patients and age- and ethnicity-matched healthy controls (2:1 ratio), all recruited from Istanbul University Medical School. To minimize confounding, we included only patients homozygous for the M694V mutation and from the same geographical region. DNA methylation profiling was performed using the Illumina Infinium MethylationEPIC v2.0 BeadChip array, covering over 930,000 CpG sites. Data analysis was conducted in R (v4.4.0), adjusting for age, sex, and cell composition.

Results: We identified 22 differentially methylated CpG sites in 32 FMF patients compared with 16 healthy controls. Of these, 18 were hypomethylated—including a CpG site within the MEFV gene—and four were hypermethylated. Notably, several differentially methylated CpGs were located in genes encoding zinc finger proteins, a family of transcriptional regulators. Of the 22 CpGs, 13 were found on chromosome 16, where MEFV is located. Three hypomethylated CpGs were within 1.1 kb of the MEFV transcription start site, two of which overlapped with enhancer regions, suggesting a potential regulatory role. Cell-type–specific analysis revealed significant differential methylation in NK cells, CD8⁺ T cells, and CD4⁺ T cells in FMF patients compared with controls.

Conclusion: Our findings suggest that DNA methylation changes may contribute to the pathogenesis of FMF. The enrichment of differentially methylated sites near MEFV on chromosome 16 and in immune cell subsets supports a role for epigenetic regulation in disease expression. These results highlight DNA methylation as a potential modifier of FMF and a promising target for future biomarker development and personalized therapeutic strategies.


Disclosures: K. Cetin Gedik: None; D. Casares Marfil: None; B. Baser Taskin: None; E. Kilic Konte: None; S. Sahin: None; M. Bowes: None; F. Guzel: None; M. Romano: None; O. Kasapcopur: None; N. Aktay Ayaz: None; E. Demirkaya: None; A. Sawalha: None.

To cite this abstract in AMA style:

Cetin Gedik K, Casares Marfil D, Baser Taskin B, Kilic Konte E, Sahin S, Bowes M, Guzel F, Romano M, Kasapcopur O, Aktay Ayaz N, Demirkaya E, Sawalha A. Genome-Wide DNA Methylation Analysis in Familial Mediterranean Fever [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/genome-wide-dna-methylation-analysis-in-familial-mediterranean-fever/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genome-wide-dna-methylation-analysis-in-familial-mediterranean-fever/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology